Related Experiment Video

Updated: May 20, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

548

STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy

Laura Gehrcken1, Christophe Deben1, Evelien Smits1

  • 1Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, 2610, Belgium.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|March 27, 2025
PubMed

Insights

Stimulators of interferon genes (STING) agonists show potential for cancer immunotherapy by activating immune responses against tumors. Combination strategies are being explored to overcome resistance in solid tumors like pancreatic cancer.

Area of Science:

  • Oncology
  • Immunology
  • Drug Development

Background:

  • Cancer remains a leading cause of death, driving the need for innovative treatments.
  • Immunotherapy is promising but faces resistance from solid tumors due to a "cold" tumor microenvironment.
  • Stimulators of Interferon Genes (STING) agonists are being developed to enhance anti-tumor immunity.

Purpose of the Study:

  • To review novel combination strategies for STING agonists in cancer immunotherapy.
  • To assess the benefits and challenges of these combination approaches.
  • To explore the potential of STING agonists in overcoming tumor resistance.

Main Methods:

  • Review of preclinical studies on STING agonists and combination therapies.
  • Analysis of STING agonist mechanisms, including immune cell infiltration and type I interferon secretion.
  • Examination of challenges in clinical translation and emerging combination strategies.

Main Results:

  • STING agonists can trigger the cancer immunity cycle, increasing type I interferon secretion and T cell activation.
  • Preclinical studies show promising results for STING agonists in inducing tumor regression.
  • Emerging combination strategies with other immunotherapies show encouraging preclinical outcomes.

Conclusions:

  • STING agonists hold significant promise for reprogramming the immune system against tumors.
  • Overcoming biological and physical challenges is crucial for clinical translation.
  • Combination strategies represent a promising avenue for enhancing STING agonist efficacy in cancer immunotherapy.
Keywords:
STING agonistscancerimmunotherapytumor microenvironmenttumor resistance

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.3K
In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.5K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
450
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
310
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
145
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K